In addition, activation of the Ras/Raf/MEK/ERK pathway coincides with a high percentage of these tumors as well, suggesting that combination inhibitor treatment along with hormone ablation could prove useful in human prostate cancer therapies [178]. Here, RAF1 is linked to prostate cancer.